Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, which aims to support the development of DPTX3186 by optimizing patient stratification through AI/ML-powered discovery and development platforms. The partnership is aligned around Dewpoint’s latest drug candidate, DPTX3186, a small molecule condensate modulator that inhibits beta catenin oncogenic function.